GPT and Thrombocytopenia: Thrombocytopenia and elevated serumconcentrations of aspartate transaminase (AST) and alanine transaminase (ALT) were the most commonly reportedgrade 3 adverse events in the ado-trastuzumab emtansine group, affecting 12.9%, 4.3%, and 2.9% of patients,respectively.